Home
HelpTest Code FPFUZ Phenosense Entry HIV Drug Resistance Assay
Reporting Name
Phenosense Entry FuzeonPerforming Laboratory
Monogram Biosciences, IncSpecimen Type
Plasma EDTASpecimen Required
Specimen Type: Plasma
Container/Tube: Lavender-top (EDTA) or plasma preparation tube (PPT)
Specimen Volume: 3 mL
Collection Instructions: Draw blood into two 5-mL PPT (pearl top) or EDTA (lavender top) tube. Centrifuge specimen within six hours of collection. Transfer plasma to one or more polypropylene screw-capped tube(s) and freeze. Freeze immediately. Send 3 mL plasma in a screw-cap vial frozen.
To avoid delays in turnaround time when requesting multiple tests, please submit separate frozen specimens for each test requested.
RECOMMENDED:
1. Patient's most recent viral load
2. Viral load collection date
NOTE: Â
1. Intended for use only for patients with viral loads greater than or equal to 500 copies/mL. For best results, viral loads should be confirmed within two weeks prior to submission for testing at Monogram.
2. Patient samples submitted <30 days apart are considered duplicate and will be canceled.
Specimen Minimum Volume
1.0 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Plasma EDTA | Frozen | 14 days |
Reference Values
A final report will be attached in MayoAccess.
Day(s) Performed
Sunday through Saturday
CPT Code Information
87903
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| FPFUZ | Phenosense Entry Fuzeon | 45182-3 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| Z1041 | Phenosense Entry Fuzeon | 45182-3 |
Report Available
18 to 30 daysReject Due To
| Other | PPT not centrifuged; insufficient volume; heparinized plasma; non frozen specimens |
Method Name
Polymerase chain reaction (PCR) amplification and viral culture.
Useful For
Determines phenotypic susceptibility to enfuvirtide (Fuzeon) and assesses likely effectiveness before enfuvirtide is added to a patient's regimen or before changing a regimen that includes enfuvirtide.